Pathos AI has launched a $400 million funding round and already raised nearly $283 million. The Chicago-based startup formed ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

CHICAGO - Tempus AI, Inc. (NASDAQ: TEM), a leader in AI-driven precision medicine with a market capitalization of $9.15 billion, announced the launch of Tempus Loop, a new platform designed to ...

Tempus AI has signed a three-way deal with AstraZeneca and Pathos AI to construct a data-based oncology model that could ...

CHICAGO, April 25, 2025--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to ...

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced publication of its study ...

The validation study recently published in the Journal of Molecular Diagnostics CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (TEM), a technology company leading the adoption of AI to advance ...

The new, proprietary target discovery platform integrates RWD, human biological modeling, and CRISPR screens to accelerate novel target identification CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ ...

CHICAGO - Tempus AI, Inc. (NASDAQ: TEM), a leader in AI-driven precision medicine with a market capitalization of $9.15 billion, announced the launch of Tempus Loop, a new platform designed to enhance ...